Dexibuprofen: pharmacology, therapeutic uses and safety
Dexibuprofen: pharmacology, therapeutic uses and safety
复制标题
DOI：
10.1163/156856003322699555
复制
发表时间：
2003-01-01
影响因子：
5.8
通讯作者：
Hesse, E.
中科院分区：
文献类型：
--
作者：
Kaehler, S. T.;Phleps, W.;Hesse, E.
地西他滨是外消旋布洛芬的唯一有效对映体。外消旋布洛芬和地塞米松在其药理学性质和代谢特征方面的理化性质不同。进行了几项临床试验和上市后监测研究，以扩大对地塞米松的研究结果。在过去5年中，4836例患者在临床试验和PMS试验中暴露于地塞米松。仅3.7%的患者报告了药物不良反应，观察到3例严重药物不良反应（0.06%）。在I：0.5的剂量比（外消旋-布洛芬与地塞米松）中，在急性轻度至重度躯体和内脏疼痛模型中证明了至少等效的疗效。已证明地西泮的疗效至少与双氯芬酸、萘普生和塞来昔布相当，并显示出良好的耐受性。结果表明，以特殊晶体形式加工的地塞米松是一种安全有效的治疗不同疼痛的方法。
Dexibuprofen is the single pharmacologically effective enantiomer of rac-ibuprofen. Rac-ibuprofen and dexibuprofen differ in their physico-chemical properties, in terms of their pharmacological properties and their metabolic profiles. Several clinical trials and post-marketing surveillance studies were performed to broaden the findings on dexibuprofen. In the last 5 years 4836 patients have been exposed to dexibuprofen in clinical trials and PMS trials. Only in 3.7% of patients adverse drug reactions have been reported and 3 serious adverse drug reactions (0.06%) were observed. In the dose ratio of I : 0.5 (rac-ibuprofen vs. dexibuprofen) at least equivalent efficacy was proven in acute mild to severe somatic and visceral pain models. Dexibuprofen has proven at least comparable efficacy to diclofenac, naproxen and celecoxib and has shown a favourable tolerability. The results suggest that dexibuprofen processed in a special crystal form is a safe and effective treatment for different pain conditions.